Amneal Pharmaceuticals Inc (AMRX) Receives Consensus Recommendation of “Hold” from Analysts

Share on StockTwits

Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) have earned a consensus rating of “Hold” from the ten research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $24.33.

Several equities analysts have commented on AMRX shares. Morgan Stanley started coverage on shares of Amneal Pharmaceuticals in a research note on Monday, July 23rd. They issued an “overweight” rating and a $22.00 price target for the company. Canaccord Genuity restated a “hold” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Tuesday, September 4th. ValuEngine downgraded shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 27th. B. Riley started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 22nd. They issued a “buy” rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a research note on Thursday, August 9th.

NYSE AMRX traded up $0.16 on Friday, reaching $18.81. The stock had a trading volume of 1,122,246 shares, compared to its average volume of 1,185,310. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of 29.86, a PEG ratio of 0.98 and a beta of 1.41. The company has a quick ratio of 1.25, a current ratio of 2.01 and a debt-to-equity ratio of 2.85. Amneal Pharmaceuticals has a 12-month low of $13.47 and a 12-month high of $24.48.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its earnings results on Thursday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $462.33 million for the quarter, compared to analyst estimates of $460.82 million. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The company’s revenue was down 2.5% on a year-over-year basis. Analysts anticipate that Amneal Pharmaceuticals will post 0.96 EPS for the current fiscal year.

In related news, CFO Bryan M. Reasons sold 11,698 shares of the business’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $23.65, for a total transaction of $276,657.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nikita Shah sold 50,000 shares of the business’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total transaction of $1,173,000.00. The disclosure for this sale can be found here. Insiders own 3.20% of the company’s stock.

Several hedge funds have recently modified their holdings of AMRX. Xact Kapitalforvaltning AB acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $203,000. Bank of Montreal Can acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $541,000. Scout Investments Inc. acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $1,752,000. Fox Run Management L.L.C. acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $228,000. Finally, Boston Advisors LLC acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $613,000. Hedge funds and other institutional investors own 32.41% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Featured Article: Do Tariffs Work?

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Amneal Pharmaceuticals Inc  Receives Consensus Recommendation of “Hold” from Analysts
Amneal Pharmaceuticals Inc Receives Consensus Recommendation of “Hold” from Analysts
Bitstar  Reaches Market Cap of $197,456.00
Bitstar Reaches Market Cap of $197,456.00
Deutsche eMark Market Capitalization Hits $274,893.00
Deutsche eMark Market Capitalization Hits $274,893.00
TGAME  Tops 1-Day Trading Volume of $105,578.00
TGAME Tops 1-Day Trading Volume of $105,578.00
ACE  Market Capitalization Achieves $666,377.00
ACE Market Capitalization Achieves $666,377.00
Zacks: Analysts Anticipate Ally Financial Inc  Will Announce Earnings of $0.80 Per Share
Zacks: Analysts Anticipate Ally Financial Inc Will Announce Earnings of $0.80 Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.